Biogen Inc. (BIIB): Price and Financial Metrics


Biogen Inc. (BIIB): $298.49

-1.70 (-0.57%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add BIIB to Watchlist
Sign Up

Industry: Biotech


Ranked

of 506

in industry

BIIB POWR Grades


  • Value is the dimension where BIIB ranks best; there it ranks ahead of 96.75% of US stocks.
  • BIIB's strongest trending metric is Momentum; it's been moving down over the last 47 weeks.
  • BIIB's current lowest rank is in the Momentum metric (where it is better than 9.67% of US stocks).

BIIB Stock Summary

  • Biogen Inc's market capitalization of $44,663,832,533 is ahead of 93.77% of US-listed equities.
  • Of note is the ratio of Biogen Inc's sales and general administrative expense to its total operating expenses; only 17.16% of US stocks have a lower such ratio.
  • As for revenue growth, note that BIIB's revenue has grown -19.25% over the past 12 months; that beats the revenue growth of merely 12.48% of US companies in our set.
  • Stocks that are quantitatively similar to BIIB, based on their financial statements, market capitalization, and price volatility, are NOK, ADI, ERIC, GRMN, and KLAC.
  • BIIB's SEC filings can be seen here. And to visit Biogen Inc's official web site, go to www.biogen.com.

BIIB Valuation Summary

  • BIIB's price/earnings ratio is 26.3; this is 27.95% lower than that of the median Healthcare stock.
  • BIIB's EV/EBIT ratio has moved down 38.1 over the prior 243 months.
  • Over the past 243 months, BIIB's price/sales ratio has gone down 36.1.

Below are key valuation metrics over time for BIIB.

Stock Date P/S P/B P/E EV/EBIT
BIIB 2021-08-31 4.3 4.7 26.3 31.2
BIIB 2021-08-30 4.4 4.8 26.8 31.7
BIIB 2021-08-27 4.4 4.8 26.7 31.6
BIIB 2021-08-26 4.4 4.7 26.6 31.5
BIIB 2021-08-25 4.4 4.8 26.6 31.5
BIIB 2021-08-24 4.5 4.8 27.1 32.1

BIIB Growth Metrics

  • Its 5 year net income to common stockholders growth rate is now at 63.35%.
  • The 2 year revenue growth rate now stands at 14.52%.
  • Its year over year net cashflow from operations growth rate is now at -50.17%.
BIIB's revenue has moved down $2,724,700,000 over the prior 15 months.

The table below shows BIIB's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-06-30 11,697.7 2,810.3 1,918.1
2021-03-31 12,604.3 3,531.5 3,011.7
2020-12-31 13,444.6 4,229.8 4,000.6
2020-09-30 14,263.3 6,557.1 5,082.4
2020-06-30 14,487.3 7,070.9 5,926.8
2020-03-31 14,422.4 7,086.4 5,878.8

BIIB's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • BIIB has a Quality Grade of B, ranking ahead of 91.68% of graded US stocks.
  • BIIB's asset turnover comes in at 0.478 -- ranking 93rd of 677 Pharmaceutical Products stocks.
  • EVOK, TMBR, and ATRA are the stocks whose asset turnover ratios are most correlated with BIIB.

The table below shows BIIB's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.478 0.839 0.098
2021-03-31 0.510 0.855 0.206
2020-12-31 0.531 0.866 0.283
2020-09-30 0.550 0.876 0.369
2020-06-30 0.545 0.880 0.415
2020-03-31 0.539 0.875 0.401

BIIB Price Target

For more insight on analysts targets of BIIB, see our BIIB price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $417.70 Average Broker Recommendation 1.64 (Moderate Buy)

BIIB Stock Price Chart Interactive Chart >

Price chart for BIIB

BIIB Price/Volume Stats

Current price $298.49 52-week high $468.55
Prev. close $300.19 52-week low $223.25
Day low $296.31 Volume 931,985
Day high $301.58 Avg. volume 1,454,312
50-day MA $330.83 Dividend yield N/A
200-day MA $295.63 Market Cap 44.48B

Biogen Inc. (BIIB) Company Bio


Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. The company was founded in 1985 and is based in Cambridge, Massachusetts.


BIIB Latest News Stream


Event/Time News Detail
Loading, please wait...

BIIB Latest Social Stream


Loading social stream, please wait...

View Full BIIB Social Stream

Latest BIIB News From Around the Web

Below are the latest news stories about Biogen Inc that investors may wish to consider to help them evaluate BIIB as an investment opportunity.

Biogen (BIIB) Reports Mixed Data From Neuropathy Pain Study

Biogen (BIIB) reports mixed data from the phase II study evaluating its non-opioid pain candidate vixotrigine for treating small fiber neuropathy.

Yahoo | September 17, 2021

CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis

VUMERITY is a next-generation oral fumarate with a well-characterized efficacy and safety profileData from the Phase 3 EVOLVE-MS-2 study have demonstrated that treatment with VUMERITY results in low discontinuation rates due to its gastrointestinal (GI) tolerability profile Upon approval, VUMERITY will offer a new oral option for MS patients as they consider treatment initiation in the context of the COVID-19 environment CAMBRIDGE, Mass., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: B

Yahoo | September 17, 2021

Biogen Reports Mixed Phase 2 Data For Its Non-Opioid Pain Candidate

Biogen Inc (NASDAQ: BIIB ) has announced topline results from its Phase 2 CONVEY study of vixotrigine (BIIB074) for small fiber neuropathy (SFN). SFN is a disorder in which only the small sensory cutaneous nerves are affected and is often characterized by severe pain that typically begins in the feet or hands. Vixotrigine is a non-opioid investigational oral pain drug. The CONVEY study 200 mg twice daily arm met its primary endpoint of change from baseline Full story available on Benzinga.com

Benzinga | September 16, 2021

Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathy

Intrado Digital Media | September 16, 2021

Biogen Inc.: Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy

Vixotrigine, a non-opioid investigational pain drug, has the potential to address significant unmet medical needs of individuals living with chronic painful neuropathyCAMBRIDGE, Mass., Sept. 16, 20

FinanzNachrichten | September 16, 2021

Read More 'BIIB' Stories Here

BIIB Price Returns

1-mo -12.66%
3-mo -20.28%
6-mo 12.35%
1-year 8.75%
3-year -13.58%
5-year 3.86%
YTD 21.90%
2020 -17.48%
2019 -1.39%
2018 -5.54%
2017 21.96%
2016 -7.43%

Continue Researching BIIB

Want to see what other sources are saying about Biogen Inc's financials and stock price? Try the links below:

Biogen Inc (BIIB) Stock Price | Nasdaq
Biogen Inc (BIIB) Stock Quote, History and News - Yahoo Finance
Biogen Inc (BIIB) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8774 seconds.